Affordable Access

deepdyve-link
Publisher Website

Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.

Authors
  • Oudiz, Ronald J1
  • Galiè, Nazzareno
  • Olschewski, Horst
  • Torres, Fernando
  • Frost, Adaani
  • Ghofrani, Hossein A
  • Badesch, David B
  • McGoon, Michael D
  • McLaughlin, Vallerie V
  • Roecker, Ellen B
  • Harrison, Brooke C
  • Despain, Darrin
  • Dufton, Christopher
  • Rubin, Lewis J
  • 1 LA Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA. [email protected]
Type
Published Article
Journal
Journal of the American College of Cardiology
Publication Date
Nov 17, 2009
Volume
54
Issue
21
Pages
1971–1981
Identifiers
DOI: 10.1016/j.jacc.2009.07.033
PMID: 19909879
Source
Medline
License
Unknown

Abstract

Two years of ambrisentan treatment was associated with sustained improvements in exercise capacity and a low risk of clinical worsening and death in patients with PAH. Ambrisentan was generally well tolerated and had a low risk of aminotransferase abnormalities over the 2-year study period. (A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 or AMB-321; NCT00578786).

Report this publication

Statistics

Seen <100 times